UK Markets close in 3 hrs 15 mins

Insights on the Point-of-Care/Rapid Diagnostics Global Market to 2027 - Featuring Abbott Laboratories, Danaher and Siemens Among Others -

·3-min read

DUBLIN, September 27, 2021--(BUSINESS WIRE)--The "Point-of-Care/Rapid Diagnostics - Global Market Trajectory & Analytics" report has been added to's offering.

Amid the COVID-19 crisis, the global market for Point-of-Care/Rapid Diagnostics estimated at US$27.9 Billion in the year 2020, is projected to reach a revised size of US$49.6 Billion by 2027, growing at a CAGR of 8.6% over the analysis period 2020-2027.

Glucose Monitoring Products, one of the segments analyzed in the report, is projected to record a 9.3% CAGR and reach US$13.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiometabolic Testing Products segment is readjusted to a revised 9.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7.6 Billion, While China is Forecast to Grow at 11.5% CAGR

The Point-of-Care/Rapid Diagnostics market in the U.S. is estimated at US$7.6 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$10.3 Billion by the year 2027 trailing a CAGR of 11.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 7.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Infectious Disease Testing Products Segment to Record 9.7% CAGR

In the global Infectious Disease Testing Products segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.5 Billion in the year 2020 will reach a projected size of US$4.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7 Billion by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

Select Competitors (Total 42 Featured):

  • Abbott Laboratories

  • AccuBioTech Co., Ltd.

  • Becton, Dickinson and Company

  • Chembio Diagnostic Systems, Inc.

  • Danaher Corporation

  • EKF Diagnostics Holdings PLC

  • Instrumentation Laboratory

  • Johnson & Johnson

  • Nova Biomedical Corporation

  • PTS Diagnostics

  • Quidel Corporation

  • Roche Diagnostics (Schweiz) AG

  • Sekisui Diagnostics LLC

  • Siemens AG

  • Trinity Biotech PLC

Key Topics Covered:




  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

  • Point-Of-Care/Rapid Diagnostics: Overview & Outlook



  • Emphasis on Decentralized Testing & Laboratory Strengthening Programs Augurs Well

  • Emergency Departments Rely on Rapid POC Diagnostics

  • Rapid POC Diagnostics Streamline Urgent Cardiac Care Settings

  • Rapid POC Diagnostics Gain Traction in Diagnosis of STD

  • Rapid POC Diagnostics for Tuberculosis Diagnosis

  • Quality Assurances Accelerate Adoption

  • Issues & Challenges




For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting